The majority of analyst ratings for Biogen are bullish or somewhat bullish, indicating a positive outlook for the stock. The average 12-month price target has also increased by 3.17% over the past month, suggesting that analysts are becoming more optimistic about the company's prospects. This is likely to have a positive short-term impact on the stock price.